NCT07564895Completed
Impact of BAFF Gene Polymorphisms on the Risk of Ulcerative Colitis and the Efficacy of Vedolizumab.
Source: ClinicalTrials.gov · Last updated 4 May 2026
Brief summary (registry, in English)
Relationships of B-cell Activating Factor Gene Polymorphisms With ulcerative colitis.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 841 (actual)
- First submitted
- 27 Apr 2026
- Start date
- 1 Mar 2018
- Primary completion date
- 30 Jun 2025
- Lead sponsor
- Second Affiliated Hospital of Wenzhou Medical University
- Diseases
- Ulcerative colitis
- NCT number
- NCT07564895
What you commit to
- Study type: Observational
- Participants enrolled: 841
- From 1 Mar 2018 to the primary completion date, 30 Jun 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- rheumatoid arthritis, systemic lupus erythematosus, intestinal tuberculosis, ischemic enteritis, radiation enteritis, tumors, etc
Who the study is looking for
- diagnosed UC based on comprehensive clinical, colonoscopy, histopathological, laboratory, and radiographic examination results
Age in the registry: 18 years to 70 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| The Second Affiliated Hospital of Wenzhou Medical University Coordinator of this site? Confirm its status | Wenzhou | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.